{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T10:50:09Z","timestamp":1792147809783,"version":"4.4.0"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","license":[{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1038\/ajg.2015.218","type":"journal-article","created":{"date-parts":[[2015,7,28]],"date-time":"2015-07-28T08:01:02Z","timestamp":1438070462000},"page":"1179-1185","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Treatment of Chronic HCV With Sofosbuvir and Simeprevir in Patients With Cirrhosis and Contraindications to Interferon and\/or Ribavirin"],"prefix":"10.14309","volume":"110","author":[{"given":"Mitchell L","family":"Shiffman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy M","family":"James","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"April G","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip C","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-17-20210210","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1056\/NEJMoa0707615","article-title":"Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon.","volume":"359","author":"Di Bisceglie","year":"2008","journal-title":"N Engl J Med"},{"key":"R2-17-20210210","doi-asserted-by":"crossref","first-page":"271","DOI":"10.7326\/0003-4819-156-4-201202210-00004","article-title":"The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007.","volume":"156","author":"Ly","year":"2012","journal-title":"Ann Intern Med"},{"key":"R3-17-20210210","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.cld.2008.07.007","article-title":"The global impact of hepatic fibrosis and end-stage liver disease.","volume":"12","author":"Lim","year":"2008","journal-title":"Clin Liver Dis"},{"key":"R4-17-20210210","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.mcna.2013.09.007","article-title":"When to consider liver transplant during the management of chronic liver disease.","volume":"98","author":"Fox","year":"2014","journal-title":"Med Clin North Am"},{"key":"R5-17-20210210","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1002\/hep.20793","article-title":"Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy.","volume":"42","author":"Everson","year":"2005","journal-title":"Hepatology"},{"key":"R6-17-20210210","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1002\/hep.23340","article-title":"Efficacy and safety of peginterferon alfa-2a (40KD) plus ribavirin in hepatitis in patients with advanced fibrosis and cirrhosis.","volume":"51","author":"Bruno","year":"2010","journal-title":"Hepatology"},{"key":"R7-17-20210210","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1053\/j.gastro.2014.03.051","article-title":"Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis.","volume":"147","author":"Hezode","year":"2014","journal-title":"Gastroenterology"},{"key":"R8-17-20210210","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jhep.2008.11.015","article-title":"Antiviral therapy increases the risk of bacterial infections in HCV infected cirrhotic patients awaiting liver transplantation: a retrospective study.","volume":"50","author":"Carrion","year":"2009","journal-title":"J Hepatol"},{"key":"R9-17-20210210","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/S0140-6736(14)60538-9","article-title":"Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial.","volume":"384","author":"Manns","year":"2014","journal-title":"Lancet"},{"key":"R10-17-20210210","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1056\/NEJMoa1214853","article-title":"Sofosbuvir for previously untreated chronic hepatitis C infection.","volume":"368","author":"Lawitz","year":"2013","journal-title":"N Engl J Med"},{"key":"R11-17-20210210","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/S0140-6736(14)61036-9","article-title":"Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study.","volume":"384","author":"Lawitz","year":"2014","journal-title":"Lancet"},{"key":"R12-17-20210210","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1056\/NEJMoa1402355","article-title":"Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis.","volume":"370","author":"Kowdley","year":"2014","journal-title":"N Engl J Med"},{"key":"R13-17-20210210","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJMoa1402454","article-title":"Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection.","volume":"370","author":"Afdhal","year":"2014","journal-title":"N Engl J Med"},{"key":"R14-17-20210210","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1056\/NEJMoa1316366","article-title":"Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection.","volume":"370","author":"Afdhal","year":"2014","journal-title":"N Engl J Med"},{"key":"R15-17-20210210","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1056\/NEJMoa1402338","article-title":"ABT-450r-ombitasvir and dasabuvir with or without ribavirin for HCV.","volume":"370","author":"Ferenci","year":"2014","journal-title":"N Engl J Med"},{"key":"R16-17-20210210","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa1402869","article-title":"ABT-450r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis.","volume":"370","author":"Poordad","year":"2014","journal-title":"N Engl J Med"},{"key":"R17-17-20210210","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJMoa1315722","article-title":"Treatment of HCV with ABT-450r-ombitasvir and dasabuvir with ribavirin.","volume":"370","author":"Feld","year":"2014","journal-title":"N Engl J Med"},{"key":"R18-17-20210210","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1056\/NEJMoa1401561","article-title":"Retreatment of HCV with ABT-450r-ombitasvir and dasabuvir with ribavirin.","volume":"370","author":"Zeuzem","year":"2014","journal-title":"N Engl J Med"},{"key":"R21-17-20210210","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJMoa1402454","article-title":"Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection.","volume":"370","author":"Afdhal","year":"2014","journal-title":"N Engl J Med"},{"key":"R22-17-20210210","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1056\/NEJMoa1316366","article-title":"Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection.","volume":"370","author":"Afdhal","year":"2014","journal-title":"N Engl J Med"},{"key":"R23-17-20210210","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa1402869","article-title":"ABT-450r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis.","volume":"370","author":"Poordad","year":"2014","journal-title":"N Engl J Med"},{"key":"R24-17-20210210","first-page":"239A","article-title":"An integrated safety and efficacy analysis of 500 patients with compensated cirrhosis treated with lepisasvirsofosbuvir with or without ribavirin.","volume":"60","author":"Bourliere","year":"2014","journal-title":"Hepatology"},{"key":"R25-17-20210210","first-page":"209A","article-title":"Ledipasvirsofosbuvir with ribavirin for the treatment of HCV in patients with post-transplant recurrence: Preliminary results of a prospective, multicenter study.","volume":"60","author":"Reddy","year":"2014","journal-title":"Hepatology"},{"key":"R26-17-20210210","doi-asserted-by":"crossref","first-page":"S187","DOI":"10.1016\/S0168-8278(15)30003-9","article-title":"Ledipasvirsofosbuvir with ribavirin is safe and efficacious in decompensated and post-liver transplant patients with HCV infection: preliminary results of the prospective SOLAR 2 trial.","volume":"62","author":"Manns","year":"2015","journal-title":"J Hepatol"},{"key":"R28-17-20210210","first-page":"220A","article-title":"Evaluation of sofosbuvir and simeprevir based regimens in the TRIO network: academic and community treatment of a real-world, heterogeneous population.","volume":"60","author":"Dieterich","year":"2014","journal-title":"Hepatology"},{"key":"R29-17-20210210","doi-asserted-by":"crossref","first-page":"677","DOI":"10.7326\/0003-4819-147-10-200711200-00003","article-title":"Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis.","volume":"147","author":"Veldt","year":"2007","journal-title":"Ann Intern Med"},{"key":"R30-17-20210210","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1002\/hep.23744","article-title":"Outcome of sustained virological responders with histologically advanced chronic hepatitis C.","volume":"52","author":"Morgan","year":"2010","journal-title":"Hepatology"},{"key":"R31-17-20210210","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.cgh.2011.03.004","article-title":"A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C.","volume":"9","author":"Backus","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R32-17-20210210","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1001\/jama.2012.144878","article-title":"Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis.","volume":"308","author":"van der Meer","year":"2012","journal-title":"JAMA"},{"key":"R33-17-20210210","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1007\/s10620-014-3422-x","article-title":"Hepatic Decompensation likely attributable to simeprevir in patients with advanced cirrhosis.","volume":"60","author":"Stine","year":"2014","journal-title":"Dig Dis Sci"},{"key":"R34-17-20210210","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1053\/j.gastro.2008.09.014","article-title":"Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease.","volume":"136","author":"Lok","year":"2009","journal-title":"Gastroenterology"},{"key":"R35-17-20210210","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/hep.27366","article-title":"Concordance of sustained virological response 4, 12, and 24 weeks post-treatment with sofosbuvir-containing regimens for hepatitis C virus.","volume":"61","author":"Yoshida","year":"2015","journal-title":"Hepatology"},{"key":"R36-17-20210210","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1053\/j.gastro.2010.07.009","article-title":"A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin.","volume":"139","author":"Swain","year":"2010","journal-title":"Gastroenterol"},{"key":"R37-17-20210210","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/jvh.12074","article-title":"Long-term clearance of hepatitis C virus following interferon -2b or peginterferon -2b, alone or in combination with ribavirin.","volume":"20","author":"Manns","year":"2013","journal-title":"J Viral Hepat"},{"key":"R38-17-20210210","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1214854","article-title":"Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options.","volume":"368","author":"Jacobson","year":"2013","journal-title":"N Engl J Med"}],"container-title":["American Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/ajg2015218.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ajg2015218","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ajg2015218.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/www.ovid.com\/00000434-201508000-00017","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T15:10:17Z","timestamp":1786547417000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00000434-201508000-00017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8]]},"references-count":35,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.1038\/ajg.2015.218","relation":{},"ISSN":["0002-9270"],"issn-type":[{"value":"0002-9270","type":"print"}],"subject":[],"published":{"date-parts":[[2015,8]]}}}